A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

NCT06956690 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma (Skin)
Non Small Cell Lung Cancer
Breast Cancer

Interventions

BIOLOGICAL: ENV-501

Sponsor

Hummingbird Bioscience